No Data
Biotech: Biotech\'s 2025 First Quarter Report
Biotech\'s 2025 First Quarter Report
Bio-Thera Solutions (688177.SH) announced its first quarter performance, with a net loss attributable to shareholders of 93.331 million yuan, a reduced loss.
Bio-Thera Solutions (688177.SH) released its first-quarter report for 2025, with revenue of 2.07...
Bio-Thera Solutions (688177.SH) reported a revenue of 0.207 billion yuan in the first quarter, an increase of 27.83% compared to the same period last year.
Gelonghui reported on April 28 that Bio-Thera Solutions (688177.SH) announced that in the first quarter of 2025, the company's revenue was 0.207 billion yuan, an increase of 27.83% year-on-year; the net loss attributable to shareholders of the listed company was 93.33 million yuan, compared to a loss of 0.119 billion yuan in the same period last year; the basic EPS was -0.23 yuan/share.
Bio-Thera Solutions Gets Nod to Trial Advanced Tumor Drug
Bio-Thera Solutions (688177.SH): Injection BAT7111 has obtained the approval notification for clinical drug trials.
Gelonghui, April 21st, Bio-Thera Solutions (688177.SH) announced that the company recently received the "Approval Notice for Clinical Trials of Pharmaceuticals" issued by the National Medical Products Administration, and the clinical trial application for the investigational drug BAT7111 for advanced solid tumors has been approved. BAT7111 is a PD-1/4-1BB bispecific antibody developed by Bio-Thera Solutions, intended for the treatment of advanced solid tumors. 4-1BB (also known as CD137) is mainly expressed on activated CD8+ effector T cells and acts as a T-cell co-stimulatory molecule, maintaining immune homeostasis and resisting immune cell apoptosis.
Bio-Thera Solutions, Ltd.'s (SHSE:688177) 26% Price Boost Is Out Of Tune With Revenues
